Empresa Brainstorm Cell Therapeutics Inc. Deutsche Boerse AG
Acciones
GHDN
US10501E2019
Biotecnología e investigación médica
Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
0,4685 EUR | +0,64 % | +8,57 % | +103,70 % |
Resumen de negocios
Número de empleados: 29
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Chaim Lebovits
CEO | Chief Executive Officer | 53 | 01/07/07 |
Alla Patlis
DFI | Director of Finance/CFO | 37 | 23/12/12 |
Chief Tech/Sci/R&D Officer | - | 12/05/22 | |
Bob Dagher
CTO | Chief Tech/Sci/R&D Officer | 55 | 17/07/23 |
Yael Gothelf
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/07 |
Stacy Lindborg
BRD | Director/Board Member | 53 | 01/06/20 |
Uri Yablonka
BRD | Director/Board Member | 47 | 06/06/14 |
General Counsel | - | 12/05/22 | |
Mary Kay Turner
LAW | General Counsel | - | 07/08/17 |
Yossef Levy
PRN | Corporate Officer/Principal | - | - |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Irit Arbel
FOU | Founder | 64 | 22/09/00 |
Uri Yablonka
BRD | Director/Board Member | 47 | 06/06/14 |
Jacob Frenkel
CHM | Chairman | 81 | 30/03/20 |
Director/Board Member | 63 | 28/10/21 | |
Director/Board Member | 61 | 05/02/18 | |
Stacy Lindborg
BRD | Director/Board Member | 53 | 01/06/20 |
Nir Naor
BRD | Director/Board Member | 50 | 20/06/23 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 70 080 523 | 60 766 674 ( 86,71 %) | 0 | 86,71 % |
Información de la empresa
Brainstorm Cell Therapeutics, Inc.
1325 Avenue of Americas 28th floor
10019, New York
+201 488 0460
http://www.brainstorm-cell.comSector
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+41,79 % | 50,93 mil M | |
-0,56 % | 42,12 mil M | |
+49,62 % | 42,05 mil M | |
-7,20 % | 29,18 mil M | |
+12,59 % | 26,02 mil M | |
-21,51 % | 18,9 mil M | |
+6,92 % | 13,21 mil M | |
+24,91 % | 12,17 mil M | |
+29,60 % | 12,16 mil M |
- Bolsa de valores
- Acciones
- Acción BCLI
- Acción GHDN
- Empresa Brainstorm Cell Therapeutics Inc.